4.7 Review

Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction JACC State-of-the-Art Review

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 78, 期 11, 页码 1166-1187

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2021.07.014

关键词

exercise intolerance; heart failure with preserved ejection fraction; senescence; skeletal muscle; aging

资金

  1. National Institute on Aging
  2. Texas Health Resources Clinical Scholarship
  3. Gilead Sciences Research Scholar Program
  4. National Institute of Aging GEMSSTAR Grant [1R03AG067960-01]
  5. Applied Therapeutics
  6. Abbott
  7. American Regent
  8. Amgen
  9. AstraZeneca
  10. Bayer
  11. Boehringer Ingelheim/Eli Lilly
  12. Boston Scientific
  13. Cytokinetics
  14. Fast BioMedical
  15. Gilead
  16. Medtronic
  17. Merck
  18. Novartis
  19. Roche
  20. Sanofi
  21. Fukuda-Denshi
  22. Bristol Myers Squibb
  23. Microsoft
  24. American Heart Association [15GPSGC-24800006]
  25. Kermit G. Phillips Endowed Chair in Cardiovascular Medicine
  26. NIH [P30 AG044271, K01AG059837, R01AG060499, R01AG058883, R01AG051376, P30AG024827, RO1 HL128526, R01-HL 121510, R33-HL-146390, R01-AG058969, 1R01HL104106, P01-HL094307, R03-HL146874, R56-HL136730, 1R01HL153646-01]
  27. The NIH [K01AG059837, R01HL145985, R21 AG051077, R01-HL 151841, R01-HL131029, 1R01HL12702801, P30AG021332, R01AG18915, R01AG045551, U24AG059624]
  28. VA grant [I01CX001636]

向作者/读者索取更多资源

Exercise intolerance (EI) is the primary manifestation of chronic heart failure with preserved ejection fraction (HFpEF), the most common form of heart failure among older individuals. The recent recognition that HFpEF is likely a systemic, multiorgan disorder that shares characteristics with other common, difficult-to-treat, aging-related disorders suggests that novel insights may be gained from combining knowledge and concepts from aging and cardiovascular disease disciplines. This state-of-the-art review is based on the outcomes of a National Institute of Aging-sponsored working group meeting on aging and EI in HFpEF. We discuss aging-related and extracardiac contributors to EI in HFpEF and provide the rationale for a transdisciplinary, gero-centric approach to advance our understanding of EI in HFpEF and identify promising new therapeutic targets. We also provide a framework for prioritizing future research, including developing a uniform, comprehensive approach to phenotypic characterization of HFpEF, elucidating key geroscience targets for treatment, and conducting proof-of-concept trials to modify these targets. (J Am Coll Cardiol 2021;78:1166-1187) (c) 2021 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据